---
title: "Zim Laboratories Ltd (ZIMLAB) — Share Price, Financials & Analysis"
symbol: "ZIMLAB"
company: "Zim Laboratories Ltd"
canonical: "https://tapetide.com/stocks/ZIMLAB"
isin: "INE518E01015"
nse_symbol: "ZIMLAB"
bse_code: "541400"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 711.24
generated_at: "2026-09-13T18:19:19.297Z"
---

# Zim Laboratories Ltd (ZIMLAB)

Canonical page: https://tapetide.com/stocks/ZIMLAB

## Company

- **NSE Symbol:** ZIMLAB
- **BSE Code:** 541400
- **ISIN:** INE518E01015
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2018-06-08
- **CEO:** Dr. Anwar Siraj Daud M.Pharm
- **Employees:** 577
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** zimlab.in

## About

Incorporated in 1989, Zim Laboratories 
Ltd manufactures formulation drugs and 
pre formulation ingredients in India and 
markets and sells these within and out
side India[1]

## Latest Price

- **Price:** ₹139.22
- **Change:** +2.79 (+2.05%)
- **Open:** ₹137.18
- **Day High:** ₹141.5
- **Day Low:** ₹132
- **Previous Close:** ₹136.43
- **Volume:** 119406
- **As Of:** 2026-09-11T10:01:37+00:00

## Key Fundamentals

Observed at 2026-09-11T04:45:53.252574Z.

- **Market Cap:** ₹711.24 Cr
- **Classification:** Microcap
- **P/E (reported):** 198
- **P/E (TTM):** 183.18
- **EPS (TTM):** ₹0.76
- **Book Value:** ₹54.77
- **Price to Book:** 2.5
- **Dividend Yield:** 0%
- **ROE:** 1.97%
- **ROCE:** 6.14%
- **Debt to Equity:** 0.43
- **Revenue (yearly):** ₹385.8 Cr
- **Net Income:** ₹5.8 Cr
- **EBITDA:** ₹41.4 Cr
- **52-Week High:** ₹144.49
- **52-Week Low:** ₹59.31
- **RSI (14):** 65.13

## Tapetide Score

- **Score:** 51 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 52 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 28.71 | 9% |
| growth | 29.58 | 9% |
| momentum | 89.06 | 12% |
| ownership | 67.63 | 24% |
| quality | 47.34 | 22% |
| valuation | 36.12 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company's working capital requirements have reduced from 52.8 days to 41.0 days

### Weaknesses

- Stock is trading at 2.52 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.03% over past five years.
- Promoter holding is low: 30.4%
- Company has a low return on equity of 4.54% over last 3 years.
- Earnings include an other income of Rs.10.9 Cr.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 20.36% | 204.24% | 0.65% |
| ebitda margin growth | -74.44% | -16.63% | -14.02% | -20.1% |
| net income growth | -208.11% | -52.46% | -44% | -17% |
| revenue growth | -14.54% | 0.26% | -2% | 4% |
| roce | -123.39% | -36.11% | -42.29% | 11.82% |
| roe | -207.49% | -59.13% | 4.67% | -76.21% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 85.83 | 96.29 | 117.86 | 81.82 | 92.14 | 96.33 | 108.73 | 71.76 | 88.71 | 108.66 | 105.27 | 94.18 |
| Expenses | 76.5 | 84.75 | 102.21 | 73.78 | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 |
| Operating Profit | 9.33 | 11.54 | 15.65 | 8.04 | 9.53 | 11.56 | 14.6 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 |
| OPM % | 10.87 | 11.98 | 13.28 | 9.83 | 10.34 | 12 | 13.43 | 5.92 | 6.49 | 11.79 | 6.83 | 2.6 |
| Other Income | 1.42 | 1.11 | 1.53 | 1 | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.7 | 6.16 | 0.99 |
| Interest | 1.22 | 1.7 | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.3 | 3.16 | 3.43 | 3.31 | 3.64 |
| Depreciation | 4.09 | 3.94 | 3.91 | 4.94 | 5 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.1 | 5.37 |
| Profit before tax | 5.44 | 7.01 | 10.99 | 1.24 | 2.96 | 5.7 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 | -5.57 |
| Tax % | 23.71 | 31.81 | 26.48 | 27.42 | 19.59 | 30 | 39.7 | -22.63 | 23.53 | 27.27 | 24.29 | -28.01 |
| Net Profit | 4.15 | 4.78 | 8.09 | 0.9 | 2.38 | 4 | 4.88 | -1.87 | -0.42 | 4.4 | 3.74 | -4.02 |
| EPS in Rs | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1 | -0.38 | -0.09 | 0.9 | 0.7 | -0.75 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 | 397 |
| Expenses | 238 | 293 | 255 | 268 | 292 | 347 | 326 | 335 | 344 | 369 |
| Operating Profit | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | 13 | 13 | 8 | 13 | 12 | 13 | 11 | 12 | 8 | 7 |
| Other Income | 9 | 2 | 5 | -3 | 4 | 6 | 5 | 6 | 11 | 11 |
| Interest | 9 | 11 | 13 | 11 | 8 | 6 | 7 | 11 | 13 | 14 |
| Depreciation | 10 | 11 | 14 | 16 | 16 | 17 | 16 | 20 | 20 | 20 |
| Profit before tax | 25 | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 | 5 |
| Tax % | 23 | 30 | -4600 | 28 | 31 | 31 | 27 | 32 | 29 | — |
| Net Profit | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 | 4 |
| EPS in Rs | — | 3.17 | 0.68 | 1.5 | 2.99 | 5.01 | 3.54 | 2.5 | 1.09 | 0.76 |
| Dividend Payout % | 4 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 | 54 |
| Reserves | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 190 | 204 | 243 |
| Borrowings | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 112 | 118 | 127 |
| Other Liabilities | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 96 | 102 | 116 |
| Total Liabilities | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Fixed Assets | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 | 162 |
| CWIP | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 70 | 96 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 | 282 |
| Total Assets | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 |
| Cash from Investing Activity | -7 | -26 | -21 | -19 | -6 | -14 | -35 | -73 | -40 | -55 |
| Cash from Financing Activity | -25 | -10 | -15 | -2 | -26 | -33 | 1 | 60 | -9 | 28 |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | 3 | 3 | -8 | 23 |
| Free Cash Flow | 24 | 8 | 15 | 3 | 25 | 34 | 1 | -57 | 1 | 11 |
| CFO/OP | 109 | 117 | 85 | 119 | 83 | 121 | 86 | 46 | 92 | 177 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 137 | 119 | 101 | 89 | 86 | 98 | 87 | 100 | 103 | 106 |
| Inventory Days | 108 | 134 | 126 | 144 | 125 | 171 | 99 | 173 | 188 | 207 |
| Days Payable | 137 | 172 | 165 | 168 | 149 | 185 | 107 | 133 | 151 | 161 |
| Cash Conversion Cycle | 108 | 81 | 63 | 65 | 62 | 85 | 79 | 140 | 140 | 152 |
| Working Capital Days | 54 | 37 | 39 | 46 | 49 | 67 | 67 | 57 | 60 | 41 |
| ROCE % | 14 | 14 | 15 | 5 | 11 | 12 | 17 | 10 | 8 | 5 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 30.34% | 30.36% |
| FIIs | 0% | 0% | 0.01% | 0% | 0% | 0.21% | 0.01% | 0.03% | 0% | 0.02% | 0% | 0.03% |
| DIIs | 0% | 0% | 0% | 0.11% | 0.1% | 0.24% | 0.24% | 0.24% | 0.24% | 0.2% | 0.07% | 1.33% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 50.74% | 50.92% | 49.01% | 49.21% | 45.48% | 44.39% | 47.78% | 47.5% | 48.2% | 36.63% | 32.77% | 31.82% |
| Others | 15.99% | 15.82% | 17.72% | 17.42% | 21.15% | 21.9% | 18.71% | 18.96% | 18.3% | 29.89% | 36.81% | 36.46% |
| No. of Shareholders | 15305 | 17342 | 17100 | 17483 | 17716 | 17450 | 17448 | 16641 | 17282 | 17251 | 16762 | 14510 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 4 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 129.54 | Buy |
| EMA (10) | 130.93 | Buy |
| SMA (20) | 125.75 | Buy |
| EMA (20) | 126.65 | Buy |
| SMA (50) | 119.55 | Buy |
| EMA (50) | 120.17 | Buy |
| SMA (100) | 112.46 | Buy |
| EMA (100) | 111.38 | Buy |
| SMA (200) | 91.71 | Buy |
| EMA (200) | 101.24 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 67.28 | Neutral |
| MACD (12,26,9) | 4.9 | Buy |
| Stochastic (14,3,3) | 78.54 | Neutral |
| ADX (14) | 29.06 | Buy |
| Williams %R (14) | -18.66 | Sell |
| ATR (14) | 7.26 | High Volatility |
| ROC (12) | 10.14 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 49.22 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ab6b0d7-64a5-4100-98a1-cb55eab82ea8.pdf) |
| 2026-08-12 | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25877940-3567-4660-a8fb-84ab3f50e578.pdf) |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b5cece5-81bc-4edc-ac17-eb8e768c0f63.pdf) |
| 2026-08-06 | [Board Meeting Outcome for Outcome Of The Board Meeting.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9218fb50-8a71-47fe-b8cc-c4662fb14375.pdf) |
| 2026-08-06 | [Earnings Presentation - Q1 FY27](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ac42384-d51f-435c-afb4-b23a8abab06c.pdf) |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07f53406-bbef-4b54-8d96-d7427d9d3870.pdf) |
| 2026-07-31 | [Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3e5ac5a-5f89-4128-bdb9-77627874f998.pdf) |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6d9f00a-5ca2-4486-a693-69b109b38aae.pdf) |
| 2026-07-13 | [Announcement under Regulation 30 (LODR)-Allotment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f627be3-a968-402e-af45-a61a278ff39e.pdf) |
| 2026-07-11 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2385cbc6-4d26-4f16-ac7e-ad2888cd860c.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c51f20e9-4dec-43f2-9215-7f23c3149c81.pdf) |
| 2026-05-23 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=afad52f8-c8b7-4d4f-8848-f2a17cef637b.pdf) |
| 2026-02-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=768539df-562f-4dcb-b6d0-063672406b86.pdf) |
| 2025-11-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=739f4e55-8299-49c7-9160-ecff5b11befc.pdf) |
| 2025-08-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=088466e8-f17f-4151-aa7f-e2480449ae6b.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dca2ec92-028c-4e7f-a28f-fa466c12474c.pdf) |
| 2024-11-15 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14ac1e7b-5375-4748-aeb5-deb8114587ee.pdf) |
| 2024-05-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f024c70f-b631-4cbd-bbdd-771c97413311.pdf) |
| 2024-02-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a179801-9d6b-43f7-abdf-0c28d34020ab.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55e38ecd-6817-47d2-9acf-cf8996970da1.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38477fbd-389b-4454-9291-ac53666d57cc.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1c0382e-e916-4c12-930f-26f45afdeb92.pdf) |
| 2025-11-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e8174cd-ddf6-4eb5-9bd1-f69457951013.pdf) |
| 2025-08-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17c161b7-8231-4c6e-a68d-5eaa2aa7acec.pdf) |
| 2025-05-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c312c898-4682-4f4d-af0b-de44c85f0764.pdf) |
| 2024-11-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d130e4f-e0b5-4760-a218-5d1b5174bf99.pdf) |
| 2024-05-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34a694b6-68b7-43a0-af37-960e5cae4044.pdf) |
| 2024-01-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90244858-7a99-490d-86a2-002dd3c5869f.pdf) |
| 2023-11-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a262fa6a-7f4e-49bc-a3c7-d3bfb80f5afe.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-06 | [Results-Financial Results For 30.06.2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9ecb2d4-7a12-4bd5-a761-6144a341167e.pdf) |
| 2026-05-19 | [Results - Financial Results For 31.03.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d65602d2-6098-4a7d-8cb5-43e3a7333ab4.pdf) |
| 2026-02-11 | [Unaudited Financial Results (Consolidated And Standalone) For The Quarter And Nine Months Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ae7ecfc-0ddb-4dc0-a6a7-0fa38aa6d7b6.pdf) |
| 2025-11-12 | [Results- Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4468e737-21d0-4a00-a0ce-d80a7fe1c530.pdf) |
| 2025-08-07 | [Results- Financial Results For Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6dad98b-228b-40e9-bdfe-2febb4a9c861.pdf) |
| 2025-05-20 | [Results - Financials For The Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14cad80a-d100-4647-a3c0-15185a2cbf5d.pdf) |
| 2025-02-10 | [Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2024 Is Enclosed Herewith.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff1c662b-6e45-49af-9bf6-b5630ef02c43.pdf) |
| 2024-11-09 | [Financial Results For The Quarter And Half Year Ended 30Th September, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a4ceb8b9-4ebb-479c-a7ae-5fe22a2fc785.pdf) |
| 2024-08-03 | [Results - Financial Results For The Quarter Ended 30Th June 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61a70e80-3ae9-476a-b13d-d03315bc06e5.pdf) |
| 2024-05-13 | [Financial Results For The Quarter And Year Ended 31St March, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ea1eb88-6e70-49cd-879a-813c52930e1c.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Zim Laboratories invested Rs 89.45 lakh in ZIMTAS Pty Ltd, raising stake to 99.96%. | [Announcement under Regulation 30 (LODR)-Updates on Acquisition 9 Apr - Zim Laboratories invested Rs 89.45 lakh in ZIMTAS Pty Ltd, raising stake to 99.96%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f716d7dc-49ef-4893-a0bb-dec01ee76c74.pdf) |
| 8 Apr - RTA confirmed Regulation 74(5) compliance for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - RTA confirmed Regulation 74(5) compliance for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/43be5b1f-82d1-449e-a422-1542064af523.pdf) |
| 30 Mar - Grant Thornton Bharat LLP appointed internal auditor for three years from FY2026-27 to FY2028-29, effective 30 Mar 2026. | [Intimation Of Appointment Of Internal Auditor Of The Company 30 Mar - Grant Thornton Bharat LLP appointed internal auditor for three years from FY2026-27 to FY2028-29, effective 30 Mar 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/939ae680-cc25-47df-993c-44c9ad75dc7c.pdf) |
| 2d - Zim Laboratories completed EU GMP inspection at Nagpur facility from 4–7 May 2026. | [Update - Completion Of EU-GMP Inspection / Audit 2d - Zim Laboratories completed EU GMP inspection at Nagpur facility from 4–7 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/abe2b84f-83dd-4d7d-8772-41d634822b05.pdf) |
| 2d - Nomination and Remuneration Committee of the Board on 08.05.2026 has approved the grant of 1,29,200 options to the eligible employee of the Company under the … | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 2d - Nomination and Remuneration Committee of the Board on 08.05.2026 has approved the grant of 1,29,200 options to the eligible employee of the Company under the …](https://www.bseindia.com/xml-data/corpfiling/AttachLive/92ac6bc7-bafa-4cd5-aeb9-34f905adccbc.pdf) |
| 23 Feb - DMCC approved dissolution of step-down subsidiary ZIM Laboratories Middle East DMCC effective 23 Feb 2026. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 23 Feb - DMCC approved dissolution of step-down subsidiary ZIM Laboratories Middle East DMCC effective 23 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9ed1a2d1-6f28-404b-b10c-0c41bc2c27dd.pdf) |
| 18 Apr - Disclosure w.r.t allotment of 48,726 equity shares pursuant to exercise of options under ZIM Laboratories Employee Stock Option Scheme 2023 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 18 Apr - Disclosure w.r.t allotment of 48,726 equity shares pursuant to exercise of options under ZIM Laboratories Employee Stock Option Scheme 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a8261001-2a37-4a8e-a8f0-a8ec8bae2403.pdf) |
| 17 Mar - ZIM Labs formed Advisory Board on 17 Mar 2026 comprising three members: Annaswamy Vaidheesh (Chair), Gautam Saigal, Girdhar Balwani. | [Announcement Under Regulation 30- Constitution Of Advisory Board 17 Mar - ZIM Labs formed Advisory Board on 17 Mar 2026 comprising three members: Annaswamy Vaidheesh (Chair), Gautam Saigal, Girdhar Balwani.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/25c24fdc-48bb-4ecc-978b-116cad7b3655.pdf) |
| 17 Feb - Transcript of Q3 & 9MFY26 Earnings Conference Call | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 17 Feb - Transcript of Q3 & 9MFY26 Earnings Conference Call](https://www.bseindia.com/xml-data/corpfiling/AttachHis/768539df-562f-4dcb-b6d0-063672406b86.pdf) |
| 17 Feb - ACUITE reaffirmed ZIM Laboratories' bank facility ratings: Rs150.23Cr LT ACUITE BBB (Stable); Rs16.00Cr ST ACUITE A3+. 17.02.2026., | [Announcement under Regulation 30 (LODR)-Credit Rating 17 Feb - ACUITE reaffirmed ZIM Laboratories' bank facility ratings: Rs150.23Cr LT ACUITE BBB (Stable); Rs16.00Cr ST ACUITE A3+. 17.02.2026.,](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d6f3dc3c-7976-45b6-9bc9-a1c6a62d6f34.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/739f4e55-8299-49c7-9160-ecff5b11befc.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/14ac1e7b-5375-4748-aeb5-deb8114587ee.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a936ad55-4ab2-42ef-a2b3-e6b83cbe8747.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a936ad55-4ab2-42ef-a2b3-e6b83cbe8747.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/afad52f8-c8b7-4d4f-8848-f2a17cef637b.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/afad52f8-c8b7-4d4f-8848-f2a17cef637b.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5c675731-eafe-4c41-ae06-294e133484cb.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dca2ec92-028c-4e7f-a28f-fa466c12474c.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f024c70f-b631-4cbd-bbdd-771c97413311.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=822afc07-28c7-451c-9a96-4d4b2e21455c.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-02-11 | [Disclosure Under Regulation- 30](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b3d21ea6-3445-47b4-8cc5-6c790dbe58ea.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e31fe51-1bf2-470c-bcec-aa53fd8d325c.pdf) |
| 2025-08-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f794103f-f48f-4ea5-8e1b-f5a940a507b8.pdf) |
| 2024-08-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b617d069-5e7a-4d98-a82d-a313381794e2.pdf) |
| 2023-08-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d0e59d81-e322-4bfb-91e2-c206066d4a08.pdf) |
| 2023-05-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=20bbee89-e99f-499b-abfd-d24eec484f12.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/db7af43e-00ff-4fa3-942c-f468f78a0893.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/84f95734-1707-4f10-93ec-7d02bd1d33a1.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c5e14074-cee6-4e97-a89f-e4e7efcb1c14.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/90d9a084-5b06-4fb3-b8e5-9ac70639d681.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/541400/74844541400.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/541400/72396541400.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/541400/67039541400.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/541400/5414000319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/541400/5414000318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/541400/5414000317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:19:19.297Z.